Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
Top Page
Beam Therapeutics
(NASDAQ:BEAM)45Neutral
Positive Factors
Clinical Progress
The early clinical data from the Phase 1/2 trial with BEAM-101 in sickle cell disease is highly encouraging and de-risks the program.
Financial Stability
The company expects a cash runway into 2027, supported by approximately $850.7 million in cash, cash equivalents, and marketable securities.
Negative Factors
Stock Rating
The rating of Beam Therapeutics, Inc. is currently Hold, indicating no immediate recommendation to buy or sell the stock.
Beam Therapeutics (BEAM) vs. S&P 500 (SPY)
Market Cap
$2.21B
Dividend YieldN/A
Average Volume (3M)1.30M
Price to Earnings (P/E)―
Beta (1Y)2.45
Revenue Growth-83.18%
EPS Growth-144.95%
CountryUS
Employees436
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.58
Shares Outstanding83,688,290
10 Day Avg. Volume1,614,310
30 Day Avg. Volume1,300,609
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)33.07
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$47.86Price Target Upside81.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Beam Therapeutics Business Overview & Revenue Model
Company DescriptionBeam Therapeutics (BEAM) is a biotechnology company that operates in the healthcare sector, focusing on the development of innovative genetic medicines. The company leverages its proprietary base editing technology to create therapies aimed at treating serious diseases at the genetic level. Beam Therapeutics' core products include a pipeline of preclinical and clinical-stage therapeutic candidates targeting various genetic disorders, including hematologic, metabolic, and ocular diseases.
How the Company Makes MoneyBeam Therapeutics primarily makes money through the advancement and commercialization of its therapeutic candidates. The company generates revenue by entering into strategic collaborations and partnerships with other pharmaceutical and biotechnology companies, which may include upfront payments, milestone payments, and royalties based on the successful development and commercialization of its therapies. Additionally, Beam may generate revenue through grants and research funding from government or private institutions. As the company progresses its pipeline, future revenue could also come from the direct sale of its approved therapies.
Beam Therapeutics Financial Statement Overview
Summary
Beam Therapeutics is experiencing robust revenue growth but continues to grapple with profitability and cash flow challenges. The balance sheet reflects a strong equity base and manageable debt levels, providing some stability. Ongoing negative cash flows and net losses present risks, requiring careful management to ensure future financial health.Income Statement
Beam Therapeutics shows significant revenue growth from 2019 to the TTM period, indicating strong top-line expansion. However, the company continues to face challenges in profitability, with negative gross profit margins in some periods and consistent net losses. The EBIT and EBITDA margins are negative, reflecting ongoing operational challenges.45
Neutral
Balance Sheet
The company maintains a strong equity position relative to assets, with a healthy equity ratio. However, the debt-to-equity ratio is moderate, suggesting manageable leverage. Beam's stockholders' equity has been growing, but persistent net losses could strain future financial stability.55
Neutral
Cash Flow
Beam Therapeutics has shown improvements in operating cash flows, though it remains negative. Free cash flow remains negative as well, indicating that cash outflows still exceed inflows. The company has managed to increase free cash flow slightly from prior periods, but it remains a concern for long-term sustainability.50
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 349.64M | 377.71M | 60.92M | 51.84M | 24.00K | 18.00K | Gross Profit |
| 327.80M | -59.67M | 38.34M | 35.40M | -103.16M | -5.39M | EBIT |
| -182.67M | -176.49M | -338.48M | -392.46M | -132.76M | -75.15M | EBITDA |
| -160.83M | -156.47M | -324.33M | -392.46M | -128.03M | -71.65M | Net Income Common Stockholders |
| -143.59M | -132.53M | -263.59M | -341.36M | -256.42M | -78.44M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.19B | 1.19B | 1.08B | 965.65M | 299.67M | 91.85M | Total Assets |
| 1.46B | 1.46B | 1.34B | 1.47B | 451.68M | 156.10M | Total Debt |
| 172.69M | 172.69M | 179.00M | 142.35M | 100.23M | 25.52M | Net Debt |
| -263.21M | -263.21M | -53.76M | -823.30M | -61.94M | -11.70M | Total Liabilities |
| 478.38M | 478.38M | 608.24M | 647.72M | 206.12M | 55.15M | Stockholders Equity |
| 981.33M | 981.33M | 733.47M | 826.74M | 245.56M | 100.94M |
| Cash Flow | Free Cash Flow | ||||
| -145.37M | -182.93M | -26.42M | -113.08M | -112.10M | -84.52M | Operating Cash Flow |
| -135.81M | -149.19M | 22.53M | -66.27M | -95.74M | -72.00M | Investing Cash Flow |
| 156.83M | 71.84M | -461.34M | -294.14M | -100.12M | -66.66M | Financing Cash Flow |
| 38.01M | 276.45M | 111.59M | 756.14M | 322.32M | 41.28M |
Beam Therapeutics Technical Analysis
Negative
26.44
Price Trends
27.13
Negative
26.28
Positive
25.75
Positive
Market Momentum
0.01
Positive
44.26
Neutral
11.46
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BEAM, the sentiment is Negative. The current price of 26.44 is below the 20-day moving average (MA) of 28.81, below the 50-day MA of 27.13, and above the 200-day MA of 25.75, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 44.26 is Neutral, neither overbought nor oversold. The STOCH value of 11.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BEAM.
Beam Therapeutics Risk Analysis
Beam Therapeutics disclosed 85 risk factors in its most recent earnings report. Beam Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Beam Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $976.55M | ― | -47.32% | ― | ― | 4.28% | |
50 Neutral | $146.11M | ― | -119.89% | ― | 150.95% | 5.48% | |
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% | |
49 Neutral | $3.73B | ― | -18.96% | ― | -89.95% | -123.71% | |
45 Neutral | $2.21B | ― | -51.36% | ― | -83.18% | -144.95% | |
39 Underperform | $941.49M | ― | -59.52% | ― | 59.55% | 3.09% | |
38 Underperform | $543.43M | ― | -40.27% | ― | 174.98% | 25.06% |
* Healthcare Sector Average
Performance Comparison
BEAM
Beam Therapeutics
26.44
-11.84
-30.93%
EDIT
Editas Medicine
1.76
-7.32
-80.62%
NTLA
Intellia Therapeutics
9.10
-20.85
-69.62%
CRSP
Crispr Therapeutics AG
43.45
-37.38
-46.25%
REPL
Replimune Group
12.02
3.01
33.41%
VERV
Verve Therapeutics
6.12
-8.95
-59.39%
Beam Therapeutics Earnings Call Summary
Earnings Call Date: Feb 25, 2025 | % Change Since: -14.13% | Next Earnings Date: May 13, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mix of significant advancements in Beam's clinical programs, particularly in sickle cell disease and liver genetic diseases, alongside notable challenges related to patient safety in ongoing trials. While the progress in clinical data and technology development is promising, the safety concerns related to conditioning agents are a critical issue.Highlights
Advancements in Sickle Cell Disease Treatment
Beam Therapeutics reported initial clinical data from the BEACON trial for BEAM-101, showing a significant increase in fetal hemoglobin (HbF) and a reduction in sickle hemoglobin (HbS) in patients with sickle cell disease. Patients achieved greater than 60% HbF, reducing HbS to less than 40%, which is consistent with sickle cell trait profiles.
Progress in Liver Genetic Disease Program
Beam-302, aimed at treating alpha-1 antitrypsin deficiency (AATD), has dosed its first patient, with plans to report initial data in 2025. This program intends to address both lung and liver manifestations of the disease.
ESCAPE Technology Development
Beam has nominated development candidates for ESCAPE technology, aiming to eliminate chemotherapy in transplants. Early nonhuman primate studies show promising engraftment and HbF induction without chemotherapy.
Strong Financial Position
Beam Therapeutics reported a strong financial position, supporting ongoing and future clinical development programs.
Lowlights
Patient Death in BEACON Trial
A patient in the BEACON trial died due to respiratory failure, likely related to busulfan conditioning. This highlights the risks associated with myeloablative conditioning in gene therapy.
Potential Safety Concerns with Conditioning
The use of busulfan in the BEACON trial has raised safety concerns, with known risks including lung injury and respiratory failure. This underscores the need for safer conditioning methods.
Company Guidance
In the Q3 2024 earnings call, Beam Therapeutics provided comprehensive updates on its clinical programs, highlighting significant progress and future expectations. The company reported that 35 patients have been enrolled in the BEACON trial for BEAM-101, with 8 patients already treated. The trial evaluates BEAM-101 for sickle cell disease, aiming for a best-in-class profile through efficient editing and induction of fetal hemoglobin (HbF) to over 60%, significantly reducing sickle hemoglobin (HbS) levels. Beam also shared promising preclinical data for its ESCAPE technology, which aims to eliminate the use of chemotherapy in stem cell transplants, potentially expanding the patient population up to fourfold. Additionally, Beam announced the completion of dosing in the first cohort of its BEAM-302 program for alpha-1 antitrypsin deficiency (AATD) and expects to report initial data in 2025. Financially, the company remains strong, supporting the continued development and potential commercialization of its pipeline.Beam Therapeutics Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
Beam Therapeutics Advances Base Editing Portfolio
Positive
Jan 13, 2025
Beam Therapeutics announced advancements in its base editing portfolio with key milestones anticipated in 2025. This progress is expected to bolster its industry positioning by advancing clinical programs, which aim to deliver life-long, curative genetic medicines, potentially impacting stakeholders through enhanced therapeutic options and financial stability.
Product-Related AnnouncementsBusiness Operations and Strategy
Beam Therapeutics Advances BEAM-101 Therapy for Sickle Cell
Positive
Dec 9, 2024
Beam Therapeutics has made significant strides in treating severe sickle cell disease, as showcased at the American Society of Hematology Annual Meeting. Their BEAM-101 therapy, part of the BEACON Phase 1/2 trial, demonstrated promising results, including significant increases in protective fetal hemoglobin and reductions in sickle hemoglobin. The therapy showed rapid engraftment and normalization of hemolysis markers, with a safety profile consistent with existing conditioning methods. These developments underline Beam’s potential in offering innovative genetic treatments for sickle cell patients.
Executive/Board ChangesBusiness Operations and Strategy
Beam Therapeutics Names Sravan K. Emany as CFO
Positive
Dec 6, 2024
Beam Therapeutics has appointed Sravan K. Emany as their new Chief Financial Officer, effective December 19, 2024. Emany brings extensive experience from his previous roles at Ironwood Pharmaceuticals and Integra LifeSciences, where he held key strategic positions. This appointment is part of Beam’s strategy to enhance its financial strength and advance its portfolio of precision genetic medicines, as the company continues to innovate in the field of gene editing. Emany’s expertise is expected to guide Beam through its next phase of growth, driving progress in its clinical pipeline.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.